The goal of this research is to understand how different types of e-cigarettes affect tobacco use. Participants will either be assigned to a control group that does not receive an e-cigarette or be assigned to receive one of two different types of e-cigarettes to sample in the lab and at home. We will measure participants' smoking and smoke exposure during the study.
Nicotine addiction is a chronic, relapsing brain disorder and although it is the leading cause of preventable premature death in the US, ~20% of adults smoke and among those that try to quit, the majority relapse.Research suggest that nicotine addiction disrupts the working in the brain involved in motivation and reward. The overarching goal of this proposal is to utilize clinical neuroscience to investigate the effects of Mindfulness Oriented Recovery Enhancement (MORE) on modifying behavior to help treat nicotine addiction.
Breath carbon monoxide (CO) can be used as an indicator of recent smoking and is measured by CO monitors. Breath CO can also be used to determine abstinence from smoking. There are several breath CO monitors commercially available, including a next generation model that connects directly to a smartphone and interfaces with a mobile application. Given the importance of comparability between different CO monitors, this study involves a comparison between three monitors to assess their agreement in CO readings and detecting abstinence from smoking.
The goal of this work is to develop, refine, and pilot test an electronic visit (e-visit) to: 1) deliver smoking cessation treatment to adults at risk for COPD and 2) to improve rates of COPD early detection and accurate diagnosis. We will conduct a pilot RCT of the COPD/smoking cessation e-visit as compared to treatment as usual (TAU), with primary objective to provide effect size estimates for a larger RCT.
Although smoking cessation interventions are increasingly moving toward remote delivery, remote assessment of smoking behavior faces one key methodological limitation: the need for biochemical verification of smoking status. To address this need, we herein will develop a remote CO data capture system through which a smartphone-enabled CO monitor (iCO™ Smokerlyzer) is integrated with REDCap. Subsequently, we will conduct a remote feasibility trial with smokers to examine: a) validity of the remote iCO™/REDCap data capture system as compared to gold-standard methods for biochemical verification of smoking and b) compliance with remote CO monitoring via the iCO™/REDCap system as applied both to episodic (i.e., once per week) and granular (i.e., once per day) data collection.
The aim is to assess the link between marketing proxies for filter ventilation (product descriptors, packaging) and risk beliefs. Ventilation is not directly promoted to consumers; rather its effects are communicated through the use of descriptive terms such as Light, Mild, and Low tar, often linked to lighter colors. Since the key terms have been restricted and replaced with others, it is important to determine which factors continue to contribute to false relative risk beliefs. We will conduct semi-structured interviews common in marketing research to test the influence of pack
descriptors and colors (as proxies for filter ventilation) on product risk perceptions and intention
The broad objective of this proposal is to use fMRI methods to conduct preliminary investigation of the effects of Clavulanic Acid on neurocognition and smoking withdrawal in abstinent cigarette smokers. This project will involve collecting data from a total of approximately 40 adult smokers.
The purpose of this project is to understand how different e-cigarettes influence their likeability and use among current smokers who try using e-cigarettes. Participants will receive an e-cigarette to sample over a three week period. During this time period they will complete daily electronic diaries and weekly lab visits. The results from this information will help us understand how different types of e-cigarettes are likely to influence cigarette and e-cigarette use.
This is a research study to find out if a smoking cessation medication, varenicline, is effective when given to smokers, remotely, as a one-time, 4-week sample.
Participants will either receive a sample of varenicline, or not. This will be decided randomly. The medicine will be mailed to participants and participants will complete 5 study contacts in addition to completing daily diaries for the first 4 weeks of the study. Participation will last 3 months.
Varenicline is a well-established medication that helps smokers quit. If participants are in the group that receives varenicline, it may help them too. But they are not required to use it, and it is completely up to them to use as they wish. Side effects from taking varenicline might include insomnia, headache, or nausea. Some individuals report negative changes in mood. Most smokers who use varenicline do not experience these symptoms.
The goal of this study is to develop, refine, and complete preliminary feasibility testing of a smoking cessation electronic visit (e-visit) for implementation in primary care/family medicine. We will conduct a feasibility RCT (n=90) of the smoking cessation e-visit as compared to treatment as usual (TAU), delivered via primary care, with primary objective to provide effect size estimates for a larger RCT. Primary outcomes cluster around: 1) treatment feasibility, 2) treatment acceptability, 3) treatment satisfaction, 4) evidence-based cessation treatment utilization, and 5) cessation-related outcomes (quit attempt incidence, abstinence). We hypothesize that participants randomized to the e-visit condition as compared to those randomized to the TAU condition will have higher rates of cessation treatment utilization (medications, counseling) and superior cessation-related outcomes.